May 9, 2024 ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update May 7, 2024 ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event May 2, 2024 ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics All Press Releases
May 9, 2024 ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 7, 2024 ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
May 2, 2024 ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics